Bergan, Stein ;
Brunet, Mercè ;
Hesselink, Dennis A...
Bergan , S , Brunet , M , Hesselink , D A , Johnson-Davis , K L , Kunicki , P K , Lemaitre , F , Marquet , P , Molinaro , M , Noceti , O , Pattanaik , S , Pawinski , T , Seger , C , Shipkova , M , Swen , J J , van Gelder , T , Venkataramanan , R , Wieland , E , Woillard , J B , Zwart , T C , Barten , M J , Budde , K , Dieterlen , M T , Elens , L , Haufroid , V , Masuda , S , Millan , O , Mizuno , T , Moes , D J A R , Oellerich , M , Picard , N , Salzmann , L , Tönshoff , B , van Schaik , R H N , Vethe , N T , Vinks , A A , Wallemacq , P , Åsberg , A & Langman , L J 2021 , ' Personalized therapy for mycophenolate : Consensus report by the international association of therapeutic drug monitoring and clinical toxicology ' , Therapeutic Drug Monitoring , vol. 43 , no. 2 , pp. 150-200 . https://doi.org/10.1097/FTD.0000000000000871.
,
2021
